Ionis Pharmaceuticals Inc Total Assets
Ionis Pharmaceuticals Inc total assets. Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) holds total assets worth $2.99 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see IONS company net worth for the company's overall valuation and market capitalisation.
Total Assets of Ionis Pharmaceuticals Inc (1990–2025)
Total assets of Ionis Pharmaceuticals Inc from 1990 to 2025. This chart illustrates how Ionis Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Ionis Pharmaceuticals Inc (IONS) stock price for real-time trading data and today's change.
Ionis Pharmaceuticals Inc - Asset Composition Analysis
Ionis Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Ionis Pharmaceuticals Inc total assets breakdown as of December 2025. Ionis Pharmaceuticals Inc's total assets of $2.99 Billion consist of 84.9% current assets and 15.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.6% |
| Accounts Receivable | $66.00 Million | 1.9% |
| Inventory | $10.05 Million | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2025)
This chart illustrates how Ionis Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Ionis Pharmaceuticals Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ionis Pharmaceuticals Inc's current assets represent 84.9% of total assets in 2025, an increase from 44.2% in 1990.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2025, down from 41.9% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Ionis Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Ionis Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Ionis Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.88 | 2.87 | 7.71 |
| Quick Ratio | 7.72 | 2.86 | 7.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.18 Billion | $1.68 Billion | $1.88 Billion |
Ionis Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Ionis Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.03 |
| Latest Market Cap to Assets Ratio | 2.05 |
| Asset Growth Rate (YoY) | 17.3% |
| Total Assets | $3.52 Billion |
| Market Capitalization | $7.23 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ionis Pharmaceuticals Inc's assets at a significant premium (2.05x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ionis Pharmaceuticals Inc's assets grew by 17.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ionis Pharmaceuticals Inc (1990–2025)
The table below shows the annual total assets of Ionis Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.52 Billion | +17.32% |
| 2024-12-31 | $3.00 Billion | +0.45% |
| 2023-12-31 | $2.99 Billion | +18.00% |
| 2022-12-31 | $2.53 Billion | -2.99% |
| 2021-12-31 | $2.61 Billion | +9.29% |
| 2020-12-31 | $2.39 Billion | -26.07% |
| 2019-12-31 | $3.23 Billion | +21.19% |
| 2018-12-31 | $2.67 Billion | +101.80% |
| 2017-12-31 | $1.32 Billion | +44.88% |
| 2016-12-31 | $912.47 Million | -4.56% |
| 2015-12-31 | $956.11 Million | +0.03% |
| 2014-12-31 | $955.81 Million | +12.83% |
| 2013-12-31 | $847.16 Million | +55.25% |
| 2012-12-31 | $545.69 Million | +12.54% |
| 2011-12-31 | $484.89 Million | -11.91% |
| 2010-12-31 | $550.48 Million | -16.24% |
| 2009-12-31 | $657.18 Million | +14.46% |
| 2008-12-31 | $574.15 Million | +121.80% |
| 2007-12-31 | $258.86 Million | +1.15% |
| 2006-12-31 | $255.91 Million | +53.82% |
| 2005-12-31 | $166.37 Million | -20.18% |
| 2004-12-31 | $208.43 Million | -37.77% |
| 2003-12-31 | $334.94 Million | -23.65% |
| 2002-12-31 | $438.68 Million | +5.18% |
| 2001-12-31 | $417.06 Million | +127.58% |
| 2000-12-31 | $183.26 Million | +77.73% |
| 1999-12-31 | $103.11 Million | +7.29% |
| 1998-12-31 | $96.10 Million | -18.49% |
| 1997-12-31 | $117.90 Million | +16.39% |
| 1996-12-31 | $101.30 Million | +1.71% |
| 1995-12-31 | $99.60 Million | +49.55% |
| 1994-12-31 | $66.60 Million | -15.48% |
| 1993-12-31 | $78.80 Million | +41.98% |
| 1992-12-31 | $55.50 Million | -24.59% |
| 1991-12-31 | $73.60 Million | +1611.63% |
| 1990-12-31 | $4.30 Million | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more